


**AMENDMENTS TO THE CLAIMS**


1-6. Canceled.

7. (Original) A method of inducing death in tumor cells, comprising contacting the cells with a compound selected from the group consisting of:

(a) a compound having the following formula:




(b) a compound having the following formula:




(c) a compound that is an analog of (a) and is selectively toxic to tumor cells.

8. (Original) A method of inducing death in cells in which the RAS pathway is activated, comprising contacting the cells with a compound selected from the group consisting of:

(a) a compound having the following formula:




(b) a compound having the following formula:




(c) a compound that is an analog of (a) and is selectively toxic to cells in which the RAS pathway is activated.

9. (Original) A method of inducing death in human cells expressing SV40 small T oncoprotein and oncogenic HRAS, comprising contacting the human cells with a compound selected from the group consisting of:

(a) a compound having the following formula:




(b) a compound having the following formula:



(c) a compound that is an analog of (a) and is selectively toxic to human cells expressing SV40 small T oncoprotein and oncogenic HRAS.


10. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the following formula:



or an analog thereof , which is selectively toxic to engineered human tumorigenic cells.

11. Canceled


12. (Currently Amended) A pharmacuetical composition comprising a pharmaceutically acceptable carrier and a compound having the following formula:




or an analog thereof , which is selectively toxic to engineered human tumorigenic cells.

13. Canceled.

14. (Currently Amended) A method of treating or preventing cancer in an individual, comprising administering to the individual a therapeutically effective amount of an agent ~~identified by the method of claim 1~~ selected from  
(a) a compound having the following formula:



(b) a compound having the following formula:



(c) a compound that is an analog of (a) and is selectively toxic to engineered human tumorigenic cells.

15. (Original) The method of claim 14, wherein the cancer is characterized by cells in which the RAS pathway is activated.
16. (Original) The method of claim 14, wherein the cancer is characterized by cells expressing SV40 small T oncoprotein; oncogenic HRAS; or SV40 small T oncoprotein and oncogenic HRAS.
17. Canceled
18. (Original) The method of claim 14, further comprising administering to the individual at least one additional anti-tumor agent that inhibits growth of the tumor cells in an additive or synergistic manner with the first agent.
- 19-66. Canceled.